Heat Biologics Stock Price

-0.03 (-2.52%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Heat Biologics Inc HTBX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.03 -2.52% 1.16 19:51:39
Close Price Low Price High Price Open Price Previous Close
1.16 1.14 1.19 1.18 1.19
Bid Price Ask Price Spread News
1.15 1.16 0.01 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,482 1,746,163 $ 1.16 $ 2,018,430 6,417,731 0.1811 - 4.30
Last Trade Time Type Quantity Stock Price Currency
19:52:36 formt 100 $ 1.16 USD

Heat Biologics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 182.10M 156.98M 153.21M $ 3.05M $ - -0.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Heat Biologics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HTBX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.,260,4620.021.75%
1 Month1.221.421.111.254,172,550-0.06-4.92%
3 Months2.1652.300.881.4111,562,398-1.01-46.42%
6 Months0.5834.300.5171.8219,848,2290.57798.97%
1 Year0.554.300.18111.5213,517,2380.61110.91%
3 Years5.726.300.18111.574,993,317-4.56-79.72%
5 Years41.3049.800.18112.813,377,389-40.14-97.19%

Heat Biologics Description

Heat Biologics Inc is a US-based immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells that secrete tumor-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.